Ivonescimab Extends Survival Over Pembrolizumab in Frontline PD-L1-Positive Lung Cancer
Start here
Akesu's bispecific antibody ivonescimab outperformed pembrolizumab head-to-head as first-line monotherapy in PD-L1-positive advanced lung cancer. Data presented at the World Conference on Lung Cancer showed a median overall survival of 30.8 months for ivonescimab versus 22.6 months for pembrolizumab, with a 27 percent reduction in the risk of death and a P value of 0.009, a statistically significant result. The outcome poses a direct survival challenge to pembrolizumab, which has long been the world's top-selling drug at $31.68 billion a year. Open questions include how regulators, prescribers and pembrolizumab's maker respond to the new survival data in this setting.
Written by a model from the reports · updated 1 day ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickHARMONi-2 Shows Positive OS for Ivonescimab in First-Line PD-L1-Positive NSCLC
At the 2026 WCLC, the HARMONi-2 study presented updated overall survival data for ivonescimab versus pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC, showing a median OS of 30.8 months and a statistically significant, clinically meaningful positive OS result. Professor Chu Qian's interpretation noted consistent benefit across subgroups, with median OS exceeding three years in patients with high PD-L1 expression.
- mp.weixin.qq.comPickIvonescimab Beats Pembrolizumab on Overall Survival in Frontline PD-L1-Positive Advanced Lung Cancer
Ivonescimab, Akesu's bispecific antibody, beat pembrolizumab head-to-head as first-line monotherapy in PD-L1-positive advanced lung cancer, with median overall survival of 30.8 months versus 22.6 months. The risk of death fell 27 percent, with P value 0.009, a statistically significant result presented at the World Conference on Lung Cancer. Pembrolizumab, long the world's top-selling drug at 31.68 billion dollars a year, now faces a direct survival challenge.
Heat trend for this story
Heat now 1·Peak in the comparable set 10 (Oct 19 20:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.